SS-31 (Elamipretide) for Mitochondrial Function — Aging
SS-31 peptide protocol targeting mitochondrial cardiolipin to improve cellular energy production and reduce oxidative stress.
Overview
SS-31 (Elamipretide) is a mitochondria-targeting peptide that binds to cardiolipin, a key phospholipid in mitochondrial membranes. This interaction improves mitochondrial function, reduces oxidative stress, and supports cellular energy production. SS-31 recently received FDA approval for the treatment of Barth syndrome, a rare genetic mitochondrial disorder. Phase 2 trials demonstrate mitochondrial ATP enhancement in heart failure and aging populations. Phase 3 trials show genotype-specific responses in mitochondrial disorders, with ongoing research to identify optimal patient populations.
Indications
- Mitochondrial dysfunction and age-related decline
- Support for cellular energy optimization
- Reduction of oxidative stress and inflammation
Mechanism of Action
Age-related cardiolipin oxidation impairs mitochondrial inner membrane structure and electron transport chain efficiency
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| SS-31 | 1 mg | Once daily | Starting dose for first 2 weeks, non-invasive delivery |
| SS-31 | 1-2 mg | Twice daily | Maintenance dose for optimal mitochondrial support |
| SS-31 | 2-4 mg | Once daily | Higher bioavailability for advanced users |
Evidence Grade
GRADE B
Safety & Contraindications
- Emerging therapeutic with ongoing clinical trials
- Generally well-tolerated in clinical studies
- Use sterile technique for all administrations